As filed with the Securities and Exchange Commission on June 29, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI ...

FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2022 Commission File Number: 001-38757 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant's name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under ...

Better Health, Brighter Future Notice of Convocation of the 146th Ordinary General Meeting of Shareholders Date: June 29, 2022 (Wednesday), 10:00 a.m. Venue: Imperial Hotel, Osaka 3rd Floor n order to prevent the spread of infection of novel coronavirus, we request you to exercise your rights in advance in writing or via the Internet, etc. as far as possible, and to refrain from coming to the venue of this General Meeting of Shareholders. If the number of shareholders coming to the venue exceeds the number ...

Better health for people, Brighter future for the world February 3, 2022 FY2021 Q3 EARNINGS ANNOUNCEMENT IMPORTANT NOTICE For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does ...

Takeda Pharmaceutical Company Limited. (NYSE:TAK) Q3 2022 Earnings Conference Call February 3, 2022 6:00 AM ET Corporate Participants Christopher OÂ'Reilly - Global Head, IR & Global Finance Christophe Weber - President and Chief Executive Officer Andy Plump - President Research and Development Costa Saroukos - Chief Financial Officer Masato Iwasaki - Japan General Affairs Ramona Sequeira - President, U.S. Business Unit and Global Portfolio Commercialization Julie Kim - President, Plasma-Derived Therapies B ...

FORM 6-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Commission File Number: 001-38757 For the month of February 2022 TAKEDA PHARMACEUTICAL COMPANY LIMITED (Translation of registrant's name into English) 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668 Japan (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports u ...

| --- | --- | --- | --- | |-------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Better health for people, | | | | | Brighter future for the world | | | | Important Notice For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q2 2022 Earnings Conference Call October 28, 2021 5:30 AM ET Company Participants Christopher OÂ'Reilly - Global Head, IR & Global Finance Christophe Weber - President and CEO Andy Plump - President Research and Development Costa Saroukos - CFO Masato Iwasaki - Japan General Affairs Ramona Sequeira - President, U.S. Business Unit and Global Portfolio Commercialization Julie Kim - President, Plasma-Derived Therapies Business Unit Conference Call Participants H ...

Takeda Pharmaceutical Co Ltd (NYSE:TAK) Q1 2022 Earnings Conference Call July 30, 2021 6:00 AM ET Company Participants Christopher O'Reilly - Global Head, IR & Global Finance Christophe Weber - President & CEO Andrew Plump - President, Research & Development Constantine Saroukos - CFO Masato Iwasaki - Representative Director Julie Kim - President, Plasma-Derived Therapies Business Unit Ramona Sequeira - President, US Business Unit & Global Portfolio Commercialization Conference Call Participants Hidemaru Ya ...

Better health for people, Brighter future for the world. FY2021 Q1 EARNINGS ANNOUNCEMENT July 30, 2021 IMPORTANT NOTICE For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does no ...